Treatment of Irritability in Huntington’s Disease

被引：0
|
作者：
Erik van Duijn
机构：
[1] GGZ Delfland,
来源：
Current Treatment Options in Neurology | 2010年 / 12卷
关键词：
Olanzapine; Valproate; Selective Serotonin Reuptake Inhibitor; Buspirone; Motor Symptom;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Irritability is a common neuropsychiatric feature of Huntington’s disease (HD), with prevalences varying from 38% to 73%. Similar prevalences of irritability are reported in other neurodegenerative disorders and traumatic brain injury, especially when the frontal lobe is involved. Before therapeutic interventions are initiated, the clinician should analyze the severity and frequency of the irritable behavior. By examining irritability in a broader spectrum, a tailor-made treatment can be provided.
引用
收藏
页码：424 / 433
页数：9
相关论文
共 50 条
  • [21] Treatment of Huntington's Disease
    Frank, Samuel
    [J]. NEUROTHERAPEUTICS, 2014, 11 (01) : 153 - 160
  • [22] Structural brain correlates of irritability and aggression in early manifest Huntington's disease
    Martinez-Horta, Saul
    Sampedro, Frederic
    Horta-Barba, Andrea
    Perez-Perez, Jesus
    Pagonabarraga, Javier
    Gomez-Anson, Beatriz
    Kulisevsky, Jaime
    [J]. BRAIN IMAGING AND BEHAVIOR, 2021, 15 (01) : 107 - 113
  • [23] Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)
    Harris, Kate L.
    Kuan, Wei-Li
    Mason, Sarah L.
    Barker, Roger A.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (06): : 622 - 630
  • [24] Evaluating the efficacy of dextromethorphan/quinidine (DM/Q) in treating irritability in Huntington's disease
    Stimming, E. Furr
    Zadegan, S. Abdollah
    Patino, J.
    Rocha, N.
    [J]. MOVEMENT DISORDERS, 2023, 38 : S390 - S391
  • [25] Treatment with memantine in Huntington's disease
    Hjermind, L. E.
    Law, I.
    Stokholm, J.
    Nielsen, J. E.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 99 - 99
  • [26] Treatment options in Huntington's disease
    Lopez-Sendon Moreno, Jose Luis
    Garcia de Yebenes, Justo
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 901 - 914
  • [27] Oligonucleotide Treatment for Huntington's Disease
    Fischbeck, Kenneth H.
    Wexler, Nancy S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2373 - 2374
  • [28] Fluoxetine in the treatment of Huntington's disease
    Nicola De Marchi
    Fabiana Daniele
    Maria Antonietta Ragone
    [J]. Psychopharmacology, 2001, 153 : 264 - 266
  • [29] Pridopidine for the treatment of Huntington's disease
    Shannon, Kathleen M.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 485 - 492
  • [30] Deutetrabenazine in the treatment of Huntington's disease
    Richard, Alby
    Frank, Samuel
    [J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2019, 9 (01) : 31 - 36
12345